San Diego>, Calif., November 14, 2012 – Researchers at the Human BioMolecular Research Institute, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and ChemRegen, Inc. have created a small molecule that convert stem cells to heart cells. Writing November 6th in the Journal of Medicinal Chemistry, the team describes how they synthesized and tested ITD-1, a man-made, drug-like chemical that can be used to generate unlimited numbers of new heart cells from stem cells.
“Because heart disease is the leading cause of death in this country, we need to effectively replace lost heart muscle cells—called cardiomyocytes,” said Mark Mercola, Ph.D., director of Sanford-Burnham’s Muscle Development and Regeneration Program and co-author of the study. “Using a small molecule to create new heart muscle cells from stem cells is very appealing.”
FuzeBox, the global leader in real-time visual collaboration solutions, today announced a number of milestones, including new customer wins, in addition to announcing the appointment of CEO Jeff Cavins to the board of directors at ChemRegen, Inc.
San Diego, Calif. (January 16, 2012) – Scientists at the Human BioMolecular Research Institute (HBRI) in San Diego, CA, and Sanford-Burnham Medical Research Institute (Sanford-Burnham) in La Jolla, CA and ChemRegen, Inc., a San Diego for-profit company focused on developing small-molecule regenerative medicines for human diseases have reported on a new set of small molecules helpful in human cardiomyocyte formation using inhibition of a biochemical signaling pathway called Wnt. The Wnt signaling pathway is a key mediator of cellular development and stem cell differentiation.
San Diego, Calif. (July 3, 2011) - Scientists from ChemRegen, Inc. were awarded a Phase I STTR grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to use chemical biology to develop small molecule “toolbox” compounds that will stimulate stem cell differentiation and produce human cardiomyocytes. Ultimately, the results from this work will provide toolbox reagents for use to grow cardiomyocytes for use in a biotechnology process to treat heart disease and to improve the safety of human drugs in development.